Edition:
United States

Flexion Therapeutics Inc (FLXN.OQ)

FLXN.OQ on NASDAQ Stock Exchange Global Market

24.58USD
21 Feb 2018
Change (% chg)

-- (--)
Prev Close
$24.58
Open
--
Day's High
--
Day's Low
--
Volume
--
Avg. Vol
369,571
52-wk High
$32.22
52-wk Low
$16.51

Chart for

About

Flexion Therapeutics, Inc. is a United States-based specialty pharmaceutical company. The Company is focused on the development and commercialization of local therapies for the treatment of patients with musculoskeletal conditions, beginning with osteoarthritis (OA), a type of degenerative arthritis. The Company's lead product... (more)

Overall

Beta: 0.73
Market Cap(Mil.): $922.75
Shares Outstanding(Mil.): 37.54
Dividend: --
Yield (%): --

Financials

  Industry Sector
P/E (TTM): -- 189.80 16.52
EPS (TTM): -- -- --
ROI: -- -0.65 36.19
ROE: -- -3.21 17.38

BRIEF-Flexion Therapeutics Announces Initial Data From Clinical Trial Evaluating Repeat Administration Of Zilretta

* FLEXION THERAPEUTICS ANNOUNCES INITIAL DATA FROM CLINICAL TRIAL EVALUATING REPEAT ADMINISTRATION OF ZILRETTA™ (TRIAMCINOLONE ACETONIDE EXTENDED-RELEASE INJECTABLE SUSPENSION)

Jan 08 2018

BRIEF-Flexion Therapeutics Enrolls First Patient In Phase 2 Pharmacokinetics And Safety Study Of Zilretta

* FLEXION THERAPEUTICS ENROLLS FIRST PATIENT IN PHASE 2 PHARMACOKINETICS AND SAFETY STUDY OF ZILRETTA™ (TRIAMCINOLONE ACETONIDE EXTENDED-RELEASE INJECTABLE SUSPENSION) IN BILATERAL OSTEOARTHRITIS OF THE KNEE Source text for Eikon: Further company coverage:

Dec 07 2017

BRIEF-Flexion therapeutics reports third-quarter results

* Flexion Therapeutics reports third-quarter 2017 financial results and recent business highlights

Nov 06 2017

BRIEF-Flexion Therapeutics announces pricing of public offering of common stock

* Flexion Therapeutics announces pricing of public offering of common stock

Oct 11 2017

BRIEF-Flexion Therapeutics- Proposed public offering of 4 mln common shares

* Flexion Therapeutics announces proposed public offering of common stock

Oct 10 2017

Flexion's knee pain drug gets FDA nod, shares hit life high

Flexion Therapeutics Inc said its injectable drug to treat osteoarthritis-related knee pain was approved by the U.S. Food and Drug Administration, sending the drug developer's shares soaring to a record high in regular trading on Friday.

Oct 06 2017

UPDATE 2-Flexion's knee pain drug gets FDA nod, shares hit life high

* Osteoarthritis drug market to hit $3.5 bln by 2026 - GlobalData

Oct 06 2017

BRIEF-Flexion Therapeutics announces FDA approval of Zilretta for osteoarthritis knee pain

* Flexion Therapeutics announces FDA approval of Zilretta (triamcinolone acetonide extended-release injectable suspension) for osteoarthritis (OA) knee pain

Oct 06 2017

Flexion's knee pain drug gets FDA nod

Oct 6 Flexion Therapeutics Inc said on Friday the U.S. Food and Drug Administration approved its drug, Zilretta, to treat moderate-to-severe osteoarthritis-related knee pain.

Oct 06 2017

BRIEF-Flexion Therapeutics says co sent a notice of termination to Astrazeneca AB regarding an out-license agreement between parties​

* Flexion Therapeutics Inc - ‍on September 8, co sent a notice of termination to Astrazeneca AB regarding an out-license agreement between parties​

Sep 14 2017

Earnings vs. Estimates